<DOC>
	<DOCNO>NCT01506765</DOCNO>
	<brief_summary>The result study `` schizophrenia , related disorder glutathione '' conduct Laboratory Psychiatric Neuroscience ( LUNEP ) DUPA Lausanne , reinforce hypothesis propose deficit intracerebral glutathione vulnerability factor Schizophrenia least subgroup patient . While pursue baseline study , appropriate try restore high level glutathione patient see increase accompany improvement symptom , particularly negative symptom disorder cognitive , particularly resistant current therapy . N-acetyl-cystein ( NAC ) precursor glutathione use clinically various indication , well tolerate even high dos . The investigator propose double-blind cross-over aim study N-acetyl-cystein ( dose oral 2g/day ) lead one hand rise glutathione brain ( measured resonance magnetic spectroscopic ) also improve patient ' condition ( determined clinical assessment , psychopathological , neuropsychological , biochemical physiological ) , record side effect . As first step , study include least thirty patient last two three year . It important note study medication suggest pharmaceutical industry , medical search .</brief_summary>
	<brief_title>Schizophrenia , Related Troubles Glutathione : Clinical Trial . Effects Oral Administration N-Acetylcysteine ( NAC ) Brain Glutathione Level Symptoms Schizophrenia</brief_title>
	<detailed_description>The result study `` schizophrenia , related disorder glutathione '' conduct Laboratory Psychiatric Neuroscience ( LUNEP ) DUPA Lausanne , reinforce hypothesis propose deficit intracerebral glutathione vulnerability factor Schizophrenia least subgroup patient . While pursue baseline study , appropriate try restore high level glutathione patient see increase accompany improvement symptom , particularly negative symptom disorder cognitive , particularly resistant current therapy . N-acetyl-cysteine ( NAC ) precursor glutathione use clinically various indication , well tolerate even high dos . The investigator propose double-blind cross-over aim study N-acetyl-cystein ( dose oral 2g/day ) lead one hand rise glutathione brain ( measured resonance magnetic spectroscopic ) also improve patient ' condition ( determined clinical assessment , psychopathological , neuropsychological , biochemical physiological ) , record side effect . As first step , study include least thirty patient last two three year . It important note study medication suggest pharmaceutical industry , medical search .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>patient ( male female , age 18 65 year , QI &gt; 70 ) meeting DSMIV criterion ( establish senior psychiatrist ) schizophrenia capacity consent study . The study population include inpatient outpatient currently take least one following : Olanzapine , Clozapine , Haloperidol , Risperidone , Flupenthixol , Fluphenazine . The following guideline establish potential medication change patient may undergo course trial . dose change exist medication ( either increase decrease dose ) accept participant allow continue trial . A change primary antipsychotic one medication another require participant withdraw study . An addiction another antipsychotic , secondary exist antipsychotic treatment ( primary antipsychotic ) acceptable provide n't complete change one antipsychotic another . pregnancy acute psychotic state , prevent patient cooperation comorbidity drug dependency organic cerebral disease , major somatic disease abnormal renal , hepatic , thyroid hematological finding treatment regulator mood ( lithium , valproate , topiramate , lamotrigine et carbamazepine ) allergy NAC treatment antioxidant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>glutathione</keyword>
	<keyword>NAC</keyword>
	<keyword>Neurological scale</keyword>
	<keyword>Magnetic Resonance Spectroscopy ( MRS )</keyword>
	<keyword>EEG/evoked potential</keyword>
	<keyword>fibroblast</keyword>
	<keyword>patient receive NAC</keyword>
	<keyword>patient receive placebo</keyword>
</DOC>